All In Biotech

Drug Trial Radar · NCT05654181

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING ORAL DOSES OF PF-07328948 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS

Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Oct 17, 2022

Primary completion

May 3, 2023

Study completion May 3, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.

Conditions

  • Healthy

Interventions

  • PF-07328948Drug

    investigational drug administered orally

  • PlaceboDrug

    Placebo matching active drug administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
  2. Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline AbnormalityTime frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
  3. Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical CriteriaTime frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
  4. Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical CriteriaTime frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
  5. Change From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate)Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
  6. Change From Baseline in ECG Parameters (PR Interval, QRS Duration, and QTcF Interval)Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Haven Clinical Research Unit

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.